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Pulmonary arterial hypertension (PAH) is a condition 
characterized by a progressive elevation of mean 
pulmonary arterial pressure to more than 25 mm of Hg at 
rest or to more than 30 mm of Hg with exercise.1 Patients 
present with exertional dyspnoea, chest pain, syncope/near 
syncope, fatigue and ultimately manifestation of right heart 
failure over months to years.2,3 
PAH is of two major types. First is primary PAH where 
there is no identifiable cause and includes idiopathic PAH 
(IPAH) and familial PAH (FPAH). Another is PAH 
secondary to left heart disease (valvular heart diseases, left 
atrial and ventricular diseases), diseases of lung which 
causing hypoxemia [Chronic obstructive Pulmonary 
Disease (COPD), Interstitial lung disease, sleep disorders, 
high altitude etc], connective tissue disorders (systemic 
sclerosis), chronic thromboembolic disease and 
generalized serious infections, e.g. HIV.4 
Pathobiology of PAH is multifactorial.5,6 Increased 
thromboxane A2, endothelin 1 and decreased Nitric oxide, 
prostacyclin (PGI2) cause vasoconstriction of small arteries 
and arterioles due to chronic hypoxemia and remodeling of 
vascular wall due to proliferation of smooth muscle cells 
and endothelial cells ( which become apoptosis resistant). 
Therapies targeted against these 2 changes provide the 
basis for current pharmacotherapy of PAH. 
Pharmacological management of PAH is generally 
unsatisfactory. Vasodilators are mainstay of therapy but 
are handicapped with a serious disadvantage. They also 
lower systemic blood pressure thus leading to lower 
pulmonary perfusion compounding hypoxemia. Various 
agents used also have adverse effects of their own. 
Currently approved therapies 4,7,8 include prostacyclin 
(PGI2: Epoprostenol), which needs to be given by 
continuous infusion due to its short half life or stable PGI2 
analogues like iloprost (given by inhalation 6-9 times per 
day) or teprostinil ( given by continuous subcutaneous. 
infusion). Oral Bosentan (endothlin receptor antagonist), 
though effective, causes serious hepatotoxicity and 
teratogenicity.8 All these drugs are very expensive too. 
The need for a cheap, oral, effective vasodilator of 
pulmonary vasculature was met by Phosphodiesterase type 
5 (PDE5) inhibitor, sildenafil, 
9.10 which when used in a 
dose of 50 mg thrice daily (much lower than dose used for 
erectile dysfunction) reduces pulmonary resistance and 
improved exercise tolerance. Low dose is effective as 
pulmonary vasculature is rich in PDE5. Benefit of sildenafil 
was also demonstrated in suitable animal models of PAH 
11 as well as patients of idiopathic PAH 12 and secondary 
PAH [13]. Oral sildenafil in low dose is now accepted mode 
of therapy for symptomatic PAH. 
ABSTRACT 
Objective: Oral sildenafil, a phosphodiesterase 5 inhibitor,is now accepted mode of therapy for symptomatic Pulmonary 
arterial hypertension(PAH).As the pathobiologic mechanisms are different in primary and secondary PAH, we undertook this 
study to find out any significant difference in efficacy of oral sildenafil therapy in primary versus secondary PAH.  
Methods: It was an unicentric parallel group longitudinal study. After selection and baseline investigations,all the patients of 
primary and secondary PAH were given sildenafil in fixed doses (50 mg thrice daily).  
Study parameters: 1. Distance covered in 6 minute walk test (6MWT), 2.Pulmonary arterial pressure (PAP) by trans-thoracic 
Doppler echocardiography, 3.quality of life (QOL) score assessed by Minnesota living with heart disease questionnaire. At the 
end of 6 weeks, 6 MWT, PAP, QOL were compared to the baseline value. 
Results: 42 subjects completed the study.20 subjects had primary PAH and 22 had secondary PAH. Sildenafil therapy was 
effective in both groups in reducing PAP, increase in distance covered in 6 minute walk and reducing QOL score. Reduction 
of PAP is significantly more in primary PAH than secondary PAH but no such difference was found in 6 MWT and QOL 
score. 
Conclusion: Though lowering of pulmonary arterial pressure in primary PAH is significantly lower than secondary PAH, this 
is not translated in better symptomatic relief. 
Key words: primary pulmonary hypertension, secondary pulmonary hypertension, sildenafil, pulmonary arterial pressure, 6 
minute walk test. 
 
Ghosh et al                                Journal of Drug Delivery & Therapeutics; 2013, 3(1), 124-127   125 
© 2011, JDDT. All Rights Reserved                                                        ISSN: 2250-1177                                                     CODEN (USA): JDDTAO 
We were intrigued by the fact that temporal evolutions of 
pathobiologic mechanisms of PAH are different in primary 
and secondary PAH. Whether this translates into any 
difference in efficacy of oral sildenafil therapy between 
two groups of PAH is an open question. Therefore we 
undertook this study to evaluate and find out any 
significant difference in efficacy of oral sildenafil therapy 
in primary versus secondary PAH. 
MATERIALS AND METHODS 
The protocol along with the informed consent form was 
approved by institutional ethics committee. Informed 
written consent was taken from all patients before 
enrolment. 
It was a unicentric parallel group longitudinal study. All 
the patients who attended the OPD or admitted in indoor 
who fulfilled all the inclusion criteria and not excluded by 
any one/more of the exclusion criteria (table 1) were 
included in the study. 
Total 42 patients were included in study, 20 with primary 
and 22 with secondary PAH. Study was continued for 
eight months. 
Study parameters: 
Primary: Distance covered in 6 minute walk test. 
(6MWT) 
Secondary:  
1.  Pulmonary arterial pressure (PAP) by trans-
thoracic Doppler echocardiography (TR jet method). 
2. Quality of life (QOL) score assessed by pre-
designed Minnesota living with heart disease 
questionnaire. 
Baseline investigations were done which included 12 lead 
electrocardiography, chest x ray, trans-thoracic Doppler 
echocardiography, walking/exercise capacity measured by 
6 minute walk test, complete hemogram and blood tests for 
urea, creatinine, total cholesterol, fasting sugar, bilirubin, 
ALT,AST, Alkaline phosphatase. Quality of life was 
assessed from standard criteria.  
After selection and baseline investigations, all the patients 
of primary and secondary PAH were given sildenafil in 
fixed doses (50 mg thrice daily). Before dispensing any 
drug, drug tolerability test was carried out. Patients were 
given 25 mg sildenafil initially and repeated after 6 hours 
under observation. If there was no hypotension, then they 
were selected to give 50 mg thrice daily and included in 
the study. 
The therapy was given for 6 weeks and patients were 
followed up every 2 weeks. At each follow up visits the 
drug was dispensed and all baseline investigations and 
tests were repeated. 
At the end of 6 weeks, 6 MWT, PAP by Doppler 
echocardiography, QOL assessment was done again and 
compared to the baseline value.  
The relevant data were collected in the form of mean + 
standard deviation. Changes in efficacy parameters at 
baseline and at the end of study were analysed using paired 
t test within same group and unpaired t test between the 
groups. The level of significance was taken as p<0.05. 
RESULTS 
Among the 42 subjects who completed the study and 
received end of trial certification, 20 subjects had primary 
PAH and 22 subjects had secondary PAH. Among 22 
secondary PAH patients, 9 cases were due to COPD, 4 
were due to bronchial asthma, 6 patients had different 
valvular and congenital heart diseases like atrial septal 
defect, 2 cases were due to interstitial lung disease and 1 
case was due to systemic sclerosis. 
Among 42 subjects, 28 patients were male and 14 were 
female. Average age of primary PAH was 18.25 years and 
of secondary PAH was 32.80 years. 
Effect on distance covered in 6 min walk test (6 MWT): 
The study showed significant increase in distance covered 
in 6 minutes on horizontal surface when the patients were 
treated with sildenafil for 6 weeks. (table 2)  
So increase in distance covered was extremely significant 
when compared with baseline value in both primary and 
secondary PAH, as measured by paired t test. But the 
increase in distance covered due to sildenafil therapy did 
not differ significantly between primary PAH and 
secondary PAH group (p value= 0.5881), when measured 
by unpaired t test. 
Effect on pulmonary arterial pressure (PAP): Sildenafil 
caused very significant reduction in pulmonary arterial 
pressure after 6 weeks therapy in both primary and 
secondary PAH when compared with the baseline values, 
when measured by paired t test. (table 3) 
The reduction in pulmonary arterial pressure was 
significantly more in patients with primary PAH than 
patients with secondary PAH (p=0.0001), as measured by 
unpaired t test.  
Effect on quality of life scores: Quality of life (QOL) 
score was assessed out of total score 105 in Minnesota 
living with heart disease questionnaire. Sildenafil therapy 
showed very significant improvement in functional 
capacity of the patients by significant lowering the QOL 
score in both primary and secondary PAH after 6 weeks of 
therapy.(table 4) 
But the reduction in QOL score due to sildenafil therapy 
for 6 weeks did not differ significantly between primary 
PAH and secondary PAH group ( p value = 0.3361), when 
measured by unpaired t test. 
DISCUSSION 
The present study shows that sildenafil citrate in 50 mg 
t.i.d. dosage is very effective in reducing Pulmonary 
arterial pressure (PAP) in patients of both primary and 
secondary PAH which is in concordance with numerous 
studies done previously. 7,13,14,15,16 We found sildenafil 
causes significantly more reduction of PAP in primary 
PAH than secondary PAH. Though changes in PAP as 
measured by Doppler echocardiography may not be 
accurate in absolute terms still the difference remains 
significant as procedural errors will have equal effect on 
both arms of the study and therefore without impact on end 
result. While we thought that the significant difference in 
PAP reduction between the two groups would have an 
impact on exercise tolerance and quality of life parameters 
in the patients, we found that it was not so. 
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We found that sildenafil was very effective in improving 
exercise tolerance in patients of PAH regardless of primary 
or secondary etiology as judged by our findings in 6 
minute walk test. (mean distance covered increased from 
307.4 m to 419.8 m in primary PAH and from 326.36 m to 
426.45 m in secondary PAH.) This is in agreement with 
SUPER study by Galie N, Ghofrani HA, Torbicki A et al 
in 200513 and other studies too 12,14 
The functional capacity of the patients was also 
significantly improved by 6 weeks sildenafil therapy as 
detected by lowering of quality of life score from baseline. 
Therefore after 6 weeks of sildenafil therapy, the 
improvement in exercise tolerance, functional capacity and 
clinical status, which in all probability was due to increase 
in cardiac output and a decrease in pulmonary vascular 
resistance, was not different regardless of etiology of PAH, 
i.e., primary or secondary causes. 
Limitations of the study are also worth a mention. Being 
parallel group study, subject matching at baseline gains 
added importance. While the matching as regards the 
degree of PAH was satisfactory but age matching was not 
possible as the average age of presentation of primary 
PAH was significantly less than that of secondary PAH 
(18.25 years and 32.80 years respectively) for obvious 
reason. 
In our study there was a preponderance of male patients 
(28 male and 14 female) but sexes were more or less 
evenly distributed between two groups. Other limitations 
were short duration of study, relatively small sample size 
and use of non-invasive efficacy parameters. However, 
submaximal exercise testing ( 6 minute walk test) is a 
popular method of evaluating efficacy of drug therapy in 
symptomatic PAH and independently related to mortality 
in primary PAH as evident from previous studies on this 
topic. 
CONCLUSION:  
Though lowering of pulmonary arterial pressure in primary 
PAH as measured by trans-thoracic echocardiography is 
significantly lower than secondary PAH, this is not 
translated in better symptomatic relief, as guided by 6 
minute walk test and quality of life score. So benefit 
acquired by sildenafil is almost equivalent in both primary 
and secondary PAH. 
 
Table 1: Subject selection criteria 
Inclusion criteria Exclusion criteria 
1. Patients with PAH of both primary 
and secondary cause. 
2. PAP is more than 30 mm of Hg. 
3. Patients with NYHA class II & III 
and are able to walk 
4. Adult age group between 12 to 75 
years of age. 
1. Patients with renal or hepatic dysfunction. 
2. Patients aged less than 12 years or more than 75 years. 
3. Weight less than 30 kg 
4. Patients showing severe hypotension on test dose with other contraindications to 
sildenafil. 
5. Patients with NYHA class IV  symptoms, coronary heart disease, severe 
hypertension. 
6. Patients taking vasodilator, especially nitrates, calcium channel blockers. 
7. Pregnant/lactating women 
8. PAH due to HIV/any severe infections. 
 
Table 2: Effect of sildenafil on 6 minute walk test 
6 min walk test Mean+S.D. before 
sildenafil (In metres) 
Mean+S.D. after sildenafil 
( In metres) 
P value 
Primary PAH 307.4 +40.13 419.8 +59.66 <0.0001 
Secondary PAH 326.36 + 62.45 426.45  +69.02 0.0002 
 
Table 3: Effect of sildenafil on Pulmonary arterial pressure 
Pulmonary arterial 
pressure 
Mean + S.D. before 
sildenafil ( in mm of Hg) 
Mean+  S.D. after 
sildenafil ( in mm of Hg) 
P value 
Primary PAH 71.8 + 11.42 37.3+ 6.04 <0.0001 
Secondary PAH 65.09+  11.46 43.18 + 11.14 <0.0001 
 
Table 4: Effect of sildenafil on quality of life 
QOL score Mean + S.D. before 
sildenafil 
Mean  +S.D. after 
sildenafil 
P value 
Primary PAH 41 +7.75 29.8+ 7.19 0.0107 
Secondary PAH 38.09 + 10.63 27.82 + 6.94 0.0005 
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